Beijing Huashitianfu Biomedical Technology

Beijing Huashitianfu Biomedical Technology is a biopharmaceutical company based in Beijing, China, specializing in the research and development of innovative therapies for respiratory and oncological conditions. The company is notably recognized for its collaboration with the China Academy of Chinese Medical Sciences in developing Huashi Baidu Granules, a treatment utilized during the COVID-19 pandemic. Its lead internal candidate, HSTF-002, is a small molecule phosphodiesterase 4 (PDE4) inhibitor currently in Phase 2 clinical trials for the treatment of chronic obstructive pulmonary disease (COPD). Huashitianfu integrates traditional medicinal knowledge with modern drug discovery platforms to advance its pipeline of chemical and botanical drugs.